Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
复制标题
紫杉醇治疗复发性或顺铂难治性睾丸癌患者的 II 期研究。
作者：
C. Bokemeyer;J. Beyer;B. Metzner;U. Ruther;A. Harstrick;L. Weissbach;U. Kohrmann;W. Verbeek;H. Schmoll
背景
BACKGROUND
Despite generally high cure rates in patients with metastatic testicular cancer, patients with incomplete responses to cisplatin-based first-line therapy or with relapsed disease have an extremely poor prognosis. Paclitaxel represents an antitumor agent with demonstrated activity in cisplatin-sensitive tumors. In addition, responses to paclitaxel have been observed in patients with platin-refractory ovarian cancers. The current phase II trial evaluates the role of paclitaxel in male patients with cisplatin-refractory or relapsed malignant germ cell tumors.
PATIENTS AND METHODS
Twenty-four patients with relapsed, mostly cisplatin-refractory metastatic testicular cancer were treated with paclitaxel as three-hour infusions of 225 mg/m2 at 3-weekly intervals. The patients had received a median of 7 platinum-containing treatment cycles (range 3-12) prior to paclitaxel and 12 patients (50%) had previously received high-dose carboplatin/etoposide-based salvage therapy with autologous stem cell support.
RESULTS
Six patients (25%) achieved major responses to paclitaxel with 2 CR (8%) and 4 PR with marker normalisation (17%). In addition, 5 patients (21%) showed disease stabilisation. Median duration of responses to paclitaxel was 8 months (3-16+). Toxicity was tolerable, with mainly granulocytopenia occurring in 50% of patients and peripheral neuropathy > or = grade II in 29%.
CONCLUSION
Paclitaxel demonstrates significant antitumor activity in 25% of patients with relapsed or cisplatin-refractory testicular cancer. Combination regimens including paclitaxel may be warranted.
登录
查看更多内容
紫杉醇在生殖细胞癌中的作用。
DOI：
--
发表时间：
1995
期刊：
Seminars in oncology.
影响因子：
--
作者：
Motzer,RJ;Chou,TC;Schwartz,L;Bosl,GJ;Bajorin,DF;Hutter,H
通讯作者：
Hutter,H
紫杉醇的 II 期试验显示出对先前接受过治疗的生殖细胞肿瘤患者的抗肿瘤活性。
DOI：
10.1200/jco.1994.12.11.2277
发表时间：
1994
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Motzer,RJ;Bajorin,DF;Schwartz,LH;Hutter,HS;Bosl,GJ;Scher,HI;Lyn,P;Fischer,P
通讯作者：
Fischer,P
影响因子：
45.3
作者：
REICHMAN, BS;SEIDMAN, AD;NORTON, L
通讯作者：
NORTON, L
影响因子：
10.3
作者：
CHOU, TC;MOTZER, RJ;BOSL, GJ
通讯作者：
BOSL, GJ
影响因子：
45.3
作者：
BROWN, T;HAVLIN, K;VONHOFF, D
通讯作者：
VONHOFF, D